TY - JOUR
T1 - High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers
AU - Yeh, Kun Huei
AU - Lin, Ming Tseh
AU - Lin, Dong Tsamn
AU - Tang, Jih Luh
AU - Lui, Louis Tak
AU - Lin, Jing Fang
AU - Chang, Yu Shiahn
AU - Cheng, Ann Lii
AU - Yu, Sen Chang
AU - Chang, King Jen
AU - Chen, Yao Chang
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1998
Y1 - 1998
N2 - High-dose therapy followed by peripheral blood stem cell (PBSC) support was performed in 29 patients with primary high-risk (Group I) or chemoresponsive metastatic (Group II) breast cancer patients. Group I patients had received PBSC mobilization within 4 weeks of modified radical mastectomy. Group II patients had to achieve minimal residual disease (MRD) by induction chemotherapy before being considered eligible for PBSC mobilization and high-dose therapy. An innovative FE120C regimen (5-FU 600 mg/m2, i.v., day 1; epirubicin 120 mg/m2, i.v., day 1; cyclophosphamide 600 mg/m2, i.v., day 1) plus G-CSF (300 μg/day, subcutaneous injection for 9 days, from day 4 post-FE120 C) was used to mobilize PBSCs. After high-dose CTCb (cyclophosphamide 6000 mg/m2, thiothepa 500 mg/m2, carboplatin 800 mg/m2, in 4 days), patients received PBSC infusion and daily C-CSF 300 μg subcutaneous injection. There were 19 and 16 patients enrolled into Group I and Group II, respectively. Ten of the Group II patients had achieved minimal residual disease (MRD) after induction chemotherapy. The median numbers of mobilized total CD34+ cells for Group I and Group II patients were 27.3 (9.2 to 114.1) x 106/kg and 17.1 (5.9 to 69.1) x 106/kg respectively. The median time to neutrophil recovery (ANC ≤ 500/μL) was 8 and 9 days in Group I and II, respectively. The median time to platelet recovery (≤ 50,000/μL) was 10 and 15 days in Group I and II, respectively. No major treatment-related toxicities were noted. In Group I, 13 out of 19 patients (68.4%; 43-87%, 95% C.I.) remained recurrence-free with a median follow-up of 31 months (6+ to 55+ months). In Group II, 3 out of 10 patients (30%; 7-65%, 95% C.I.) remained progression-free at 33+, 35+, 39+ months from induction therapy. We suggest that the FE120C plus G-CSF is an effective and innovative regimen for PBSC mobilization in breast cancer patients, and high-dose CTCb therapy with PBSC support is a safe and well-tolerated treatment modality.
AB - High-dose therapy followed by peripheral blood stem cell (PBSC) support was performed in 29 patients with primary high-risk (Group I) or chemoresponsive metastatic (Group II) breast cancer patients. Group I patients had received PBSC mobilization within 4 weeks of modified radical mastectomy. Group II patients had to achieve minimal residual disease (MRD) by induction chemotherapy before being considered eligible for PBSC mobilization and high-dose therapy. An innovative FE120C regimen (5-FU 600 mg/m2, i.v., day 1; epirubicin 120 mg/m2, i.v., day 1; cyclophosphamide 600 mg/m2, i.v., day 1) plus G-CSF (300 μg/day, subcutaneous injection for 9 days, from day 4 post-FE120 C) was used to mobilize PBSCs. After high-dose CTCb (cyclophosphamide 6000 mg/m2, thiothepa 500 mg/m2, carboplatin 800 mg/m2, in 4 days), patients received PBSC infusion and daily C-CSF 300 μg subcutaneous injection. There were 19 and 16 patients enrolled into Group I and Group II, respectively. Ten of the Group II patients had achieved minimal residual disease (MRD) after induction chemotherapy. The median numbers of mobilized total CD34+ cells for Group I and Group II patients were 27.3 (9.2 to 114.1) x 106/kg and 17.1 (5.9 to 69.1) x 106/kg respectively. The median time to neutrophil recovery (ANC ≤ 500/μL) was 8 and 9 days in Group I and II, respectively. The median time to platelet recovery (≤ 50,000/μL) was 10 and 15 days in Group I and II, respectively. No major treatment-related toxicities were noted. In Group I, 13 out of 19 patients (68.4%; 43-87%, 95% C.I.) remained recurrence-free with a median follow-up of 31 months (6+ to 55+ months). In Group II, 3 out of 10 patients (30%; 7-65%, 95% C.I.) remained progression-free at 33+, 35+, 39+ months from induction therapy. We suggest that the FE120C plus G-CSF is an effective and innovative regimen for PBSC mobilization in breast cancer patients, and high-dose CTCb therapy with PBSC support is a safe and well-tolerated treatment modality.
KW - Breast cancer
KW - High-dose therapy
KW - Mobilization regimen
KW - PBSC support
UR - http://www.scopus.com/inward/record.url?scp=7344230475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7344230475&partnerID=8YFLogxK
U2 - 10.1023/A:1006023731381
DO - 10.1023/A:1006023731381
M3 - Article
C2 - 9776507
AN - SCOPUS:7344230475
SN - 0167-6806
VL - 49
SP - 237
EP - 244
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -